Regenics
Develops marine-derived wound care products for treating burns and chronic wounds
Highlights
- New on EvolcAdded 2026-10-28
About Regenics
Regenics develops wound care products using marine ingredients. Its pipeline includes Collex, a wound dressing, and Vernex, a hydrogel wound spray, both in preclinical development.
The products are intended to treat partial-thickness burns and chronic wounds. Regenics is also developing WoundClear, an investigational drug derived from trout enzymes for wound debridement, which is at the discovery stage.
Regenics was founded in 2000 and is based in Oslo, Norway.
Product: Collex and Vernex are wound care medical devices in development; WoundClear is an investigational drug for enzymatic wound debridement.
Jobs at Regenics
More biotech & pharma companies
Thor Medical
Produces thorium-derived alpha-particle emitters for makers of radioligand cancer therapies and research usersNew on EvolcTribune Therapeutics
Preclinical biopharma developing anti-fibrotic medicines that target CCN signaling, for patients with fibrotic diseaseNew on EvolcVitas
Contract analytical lab in Oslo running DBS biomarker analysis and GMP pharma quality testing for drug, food and research clientsNew on EvolcZelluna
Clinical-stage biotech developing TCR-guided NK cell therapies for solid cancers, led by ZI-MA4-1 in a Phase 1 trialNew on EvolcZenit Science
Life science research and contract services for drug developers and researchers working on serious diseasesYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Tilda
- jQuery